Active substance |
sebelipase alfa |
Holder |
Alexion Pharma International Trading |
Status |
Running |
Indication |
treatment of paediatric and adult patients with lysosomal acid lipase deficiency (LAL-D) who participated to the open label phase 2 study (LAL-C06) |
Public documents |
|
Last update |
10/07/2023 |
Kanuma
Last updated on